摘要
目的:艾迪注射液联合新辅助化疗后手术在软组织肉瘤患者中的疗效及其对外周血淋巴细胞亚型水平的影响。方法:前瞻性选择2015年3月—2018年3月以软组织肉瘤收治的患者140例作为对象,分为对照组(n=70)和观察组(n=70)。对照组联合新辅助化疗治疗,观察组在对照组基础上联合艾迪注射液治疗,两组均接受1个月新辅助化疗治疗,治疗完毕后再行手术。参考实体瘤疗效率标准分别以完全缓解(CR)、部分缓解(PR)、稳定(SD)及进展对患者近期疗效率进行评估;采用流式细胞仪评估两组治疗前、治疗后1个月CD3+,CD4+,CD8+,CD4+/CD8+外周血淋巴水平;治疗后对患者进行12个月随访,记录并统计两组治疗后复发率、毒副反应发生率及生存期,比较两组临床疗效及对外周血淋巴细胞亚型水平的影响。结果:观察组新辅助化疗后手术前的疗效率为62.86%,高于对照组41.18%(P<0.05)。观察组治疗后1个月CD3+,CD4+,CD4+/CD8+水平均高于对照组(P<0.05);观察组治疗后1个月CD8+水平低于对照组(P<0.05)。观察组治疗后12个月复发率低于对照组(P<0.05);观察组与对照组治疗后12个月骨髓抑制、静脉炎、重度腹泻及恶心呕吐差异无统计学意义(P>0.05)。观察组无进展生存期为(4.49±0.84)个月,长于对照组(2.57±0.63)个月(P=0.028)。结论:将艾迪注射液联合新辅助化疗后手术治疗用于软组织肉瘤患者中能获得较高的近期疗效,能促进患者外周血淋巴细胞亚型水平平衡,有助于降低复发率和毒副反应发生率,延长患者生存期,值得推广应用。
Objective:To investigate the effect of Aidi injection combined with neoadjuvant chemotherapy in patients with soft tissue sarcoma and the influence on peripheral blood lymphocyte level.Methods:Seventy patients with soft tissue sarcoma from March 2015 to March 2018 were selected and divided into control group(n=70)and observation group(n=70).Surgical treatment was performed in both groups.The control group was treated with neoadjuvant chemotherapy.The observation group was treated with Aidi injection additionally.The two groups were treated for 1 month.The response of the patients was evaluated after treatment as complete response(CR),partial remission(PR),stable disease(SD)and progression,respectively,referring to the evaluation method of solid tumors.Flow rate cytometry was used to measure the peripheral blood lymphocyte levels of CD+3,CD4+,CD8+,and CD4+/CD8+before treatment and 1 month after treatment.After treatment,the patients werefollowed up for 12 months.The recurrence rate,incidence of toxicity and survival time of the two groups were recorded and counted.Statistical analysis was conducted to compare the efficacy and peripheral blood lymphocyte level.Results:The effective rate of the observation group after neoadjuvant chemotherapy and before surgery was 62.86%,which was higher than that of the control group(41.18%,P<0.05).The levels of CD+3,CD4+and CD4+/CD8+in the observation group were higher than those in the control group at 1 month after treatment(P<0.05).The level of CD8+in the observation group was lower than that in the control group(P<0.05).The recurrence rate of the observation group at 12 months after treatment was lower than that of the control group(P<0.05).There was no significant difference in myelosuppression,phlebitis,severe diarrhea and nausea and vomiting between the observation group and the control group at 12 months(P>0.05).The progression-free survival period of the observation group was(4.49±0.84)months,which was longer than that(2.57±0.63 months)of the control group(P=0.028).Con
作者
范晓杰
冯建刚
蒋怡芳
霍炳杰
张子博
FAN Xiao-jie;FENG Jian-gang;JIANG Yi-fang;HUO Bing-jie;ZHANG Zi-bo(Department of Orthopedics,,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Respiration,,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Traditional Chinese Medicine,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2019年第15期1846-1851,共6页
Chinese Journal of New Drugs
基金
河北省中医药管理局科研计划项目(2018141)
关键词
艾迪注射液
手术治疗
软组织肉瘤
近期疗效
外周血淋巴水平
复发率
毒副反应
生存期
Aidi injection
surgical treatment
soft tissue sarcoma
short-term efficacy
peripheral blood lymphocyte level
recurrence rate
toxic side effects
survival period
